US20230381119A1

US20230381119A1 - Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents

Info

Publication number: US20230381119A1
Application number: US18/131,979
Authority: US
Inventors: Michael Bergel; James E. Johnson; Debra Dolliver; Sudheer Dhanireddy; Amon Gekombe
Original assignee: Texas Woman's University
Current assignee: Texas Woman's University
Priority date: 2017-10-02
Filing date: 2023-04-07
Publication date: 2023-11-30
Also published as: US20210023028A1; US11648217B2

Abstract

Described herein is the use of bisamidoximes compounds for the treatment of HAT malfunction related pathologies.

Description

PRIORITY CLAIM

This application is a continuation of U.S. patent application Ser. No. 17/008,617 entitled “USE OF HISTONE ACETYLTRANSFERASE INHIBITOR AMIDOXIMES AS ANTI-PROLIFERATIVE AGENTS” filed Aug. 31, 2020, which is a continuation-in-part of U.S. patent application Ser. No. 16/149,892 entitled “USE OF HISTONE ACETYLTRANSFERASE INHIBITOR AMIDOXIMES AS ANTI-PROLIFERATIVE AGENTS” filed Oct. 2, 2018, which issued as U.S. Pat. No. 10,758,501 on Sep. 1, 2020, which claims the benefit of priority to U.S. Provisional Application Ser. No. 62/567,089 entitled “USE OF HISTONE ACETYLTRANSFERASE INHIBITOR AMIDOXIMES AS ANTI-PROLIFERATIVE AGENTS” filed Oct. 2, 2017, which are hereby incorporated by reference in their entirety as though fully and completely set forth herein.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention generally relates to use of bisamidoximes as histone acetyltransferase inhibitors.

2. Description of the Relevant Art

Lung cancer, breast cancer, and colon cancer are three types of common cancer, which are estimated to be among the top four causes of cancer-related deaths during 2017. For instance, in 2017, it is estimated that 255,180 new cases of breast cancer will be diagnosed in the USA (in women and men), and 41,070 breast cancer patients will die, making it the most common cancer diagnosed, and the fourth deadliest cancer.

In the cell, the long double-helical DNA strands are packed into a complex structure associated with various proteins and RNA. This structure, named chromatin, is folded into several levels. Each level of folding increases the compactness and tightness of the packed DNA. Unfolding of this tightly packed chromatin is important for all DNA-mediated functions, such as producing RNA transcripts (transcription), replicating new DNA strands (replication), and repairing damages within the DNA. The unfolding of DNA enables the accessibility of large protein complexes that carry out these tasks. The basic repetitive packaging unit of chromatin is a beadlike core particle composed of 8 positively charged proteins, called core histones, upon which the DNA is wound approximately twice. These beads repeat themselves millions of times in the chromatin, linked by starches of DNA between each consecutive bead, in a basic form described as “beads on a string.” The core particle (the bead), with the two linker DNA segments extending from it, is called a nucleosome. The width of this first basic level of chromatin fiber is 10 nm (nanometer). The negatively charged DNA is attracted to the core histones by virtue of their positive charges and by formation of hydrogen bonds.

Folding the chromatin from the 10 nm fiber to the 30 nm fiber is a dynamic and reversible process that is very accurately regulated temporally and spatially during embryonic development, during cellular growth and differentiation, and in response to environmental cues.

The 30 nm chromatin fiber is a more compact form that represses the activation of genes (transcription). This transcription repression by the 30 nm fiber is crucial for regulating the normal development and activity of the cell. Some subsets of genes are activated and others are silenced in a very tightly orchestrated manner. The silencing of protein production of some genes is not less critical for the cell than the activation of others. For instance, cancer can develop when some genes, known as oncogenes, stop being repressed.

One of the major mechanisms for unfolding and folding chromatin is by acetylation and deacetylation of the tails of the core histones, respectively. Deacetylation and consequently folding of chromatin is carried out by a group of enzymes named histone deacetylases (HDACs). These HDACs are involved in removing the acetyl groups from the core histones and enabling a higher attraction between the more positively charged core histones and the DNA, which result in an increase of the compaction. There are four classes of HDACs and 11 known HDACs in the zinc-dependent HDAC classes I, II and IV. The activity of HDACs is reversed by another group of enzymes named Histone acetyltransferases (HATs), which are involved in unfolding chromatin. HATs act by adding an acetyl group to the core histones and consequently neutralizing the positive charge of the histones and alleviating the strong interaction between the negatively charged DNA and the less positively charged histones.

FIG. 1 shows how the steady-state of histone acetylation is maintained by opposing activities of histone acetyltransferases and deacetylases. Acetylation is the transfer of the acetyl moiety from an acetyl coenzyme A donor to the side chain of a lysine residue in an acceptor protein. This is an example of a post-translational modification of a protein, since this chemical change happens in the mature protein and not as part of its synthesis. The steady state of histone acetylation is maintained by the opposing activities of two groups of enzymes, HATs, that add the acetyl group and HDACs that remove it.

In recent years, many research groups have focused their attention on the discovery of drugs that inhibit HDACs and can inhibit the growth of malignant cells. Some of these drugs are already in clinical use. Compounds that inhibit HATs were also discovered, and they, as well, caused a selective growth inhibition and death of malignant cells. Furthermore, recently there have been several reports that the dietary compound curcumin inhibits the activity of the histone acetyltransferase p300 and prevents heart failure in animals. Potential HAT malfunction related pathology has been demonstrated in a variety of diseases such as Alzheimer, diabetes, hyperlipidaemia, as well as in asthma, and COPD, making HAT inhibitors sought-after compounds. Despite the progress made in understanding the structure of HATs, such as p300, their enzymatic mechanism and the way the HATs are inhibited is essentially unclear. Also, several HAT inhibitors demonstrated reactivity, instability, low potency, and lack of selectivity between HAT subtypes and other enzymes.
There is a continuing need for new anti-cancer compounds, since the existing compounds are not curing all cases of cancer and have numerous negative side effects. Furthermore, many of the currently used chemotherapeutic agents result in a drug resistance response in patients, in which case the patient's tumors stop responding to the treatment. Histone modifiers, such as Attv. Dkt. No.: 7142-00503 Page 3 Kowert, Hood, Munyon, Rankin & Goetzel HDAC inhibitors and HAT inhibitors, are sought-after compounds, since many of them specifically target malignant cells by either suppressing oncogenes or inducing the expression of tumor-suppressor genes. Some of these compounds are already in clinical use, especially HDAC inhibitors. However, there is still a need for anti-cancer compounds exhibiting superior effectiveness while minimizing side effects associated with many anti-cancer compounds.

SUMMARY OF THE INVENTION

In an embodiment, a method of treating cancer in a subject comprises administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising one or more bisamidoximes.
In one embodiment, one or more of the bisamidoximes have the structure:
where W: is —(CH₂)₂—; —(CH₂)₃—; —(CH₂)₄—; or —(CH₂)₃—N(CH₃)—(CH₂)₃—; and where Y is H, C₁-C₆alkyl, or halogen. In one embodiment, Y is methyl.
In one embodiment, one or more of the bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB 7, and JJMB 9:
In one embodiment, the pharmaceutical composition comprises two or more bisamidoximes. The pharmaceutical composition may comprise JJMB5 and JJMB 9, JJMB5 and JJMB7, orJJMB7 and JJMB9.
In one embodiment, the cancer is breast cancer, lung cancer, or colon cancer.
In one embodiment, a method of treating cancer in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising an anticancer agent and one or more bisamidoximes. In one embodiment, the anticancer agent is cisplatin.
In one embodiment, a method of inhibiting histone acetyltransferases (HATs) in a biomedical application, comprising applying an effective amount of a composition comprising one or more bisamidoximes to a biomedical application that includes HATs.

BRIEF DESCRIPTION OF THE DRAWINGS

Advantages of the present invention will become apparent to those skilled in the art with the benefit of the following detailed description of embodiments and upon reference to the accompanying drawings in which: FIG. 1 depicts a schematic diagram of how the steady-state of histone acetylation is maintained by opposing activities of histone acetyltransferases and deacetylases;
FIG. 2 depicts a graph of mammary tumor volumes in JJMB7 treated and untreated control BALB/c mice;
FIG. 3 is a graph depicting the effect of compound JJMB9 on breast cancer tumor volume;
FIG. 4 depicts the daily weight of mice during treatment with compound JJMB9;
FIG. 5 depicts the effect of compound JJMB9 on Mouse Liver Microsomes;
FIG. 6 depicts the effect of JJMB 5, 6, 7, 9 and garcinol on cellular core histone acetylation;
FIG. 7A depicts the percentage of standardized acetylation on H3K9;
FIG. 7B depicts the percentage of standardized acetylation on H4K5;
FIG. 8 depicts a schematic diagram of the inhibition of HDACs by TSA and how this induces hyperacetylation of core histones;
FIG. 9A shows how the amidoxime JJMB 5 reverses TSA induced hyperacetylation;
FIG. 9B shows how the amidoxime JJMB 6 reverses TSA induced hyperacetylation;
FIG. 9C shows how the amidoxime JJMB 7 reverses TSA induced hyperacetylation;
FIG. 9D shows how the amidoxime JJMB 9 reverses TSA induced hyperacetylation;
FIG. 9E shows how garcinol reverses TSA induced hyperacetylation;
FIG. 10A depicts the results from a test studying the effects of reversing the TSA effect by the amidoxime JJMB5;
FIG. 10B depicts the results from a test studying the effects of reversing the TSA effect by the amidoxime JJMB6;
FIG. 10C depicts the results from a test studying the effects of reversing the TSA effect by the amidoxime JJMB9;
FIG. 10D depicts the results from a test studying the effects of reversing the TSA effect by the amidoxime JJMB7;
FIG. 10E depicts the results from a test studying the effects of reversing the TSA effect by garcinol;
FIG. 11 depicts a diagram showing the experimental design of the in vitro HAT assay in the presence and absence of inhibitor;
FIG. 12 depicts results of the in vitro P300 inhibition assay;
FIG. 13 depicts the percentage of standardized acetylation of H4K5; and
FIG. 14 depicts the results of the in vitro GCN5 inhibition assay.
While the invention may be susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and will herein be described in detail. The drawings may not be to scale. It should be understood, however, that the drawings and detailed description thereto are not intended to limit the invention to the particular form disclosed, but to the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention as defined by the appended claims.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

It is to be understood the present invention is not limited to particular devices or methods, which may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include singular and plural referents unless the content clearly dictates otherwise. Furthermore, the word “may” is used throughout this application in a permissive sense (i.e., having the potential to, being able to), not in a mandatory sense (i.e., must). The term “include,” and derivations thereof, mean “including, but not limited to.” The term “coupled” means directly or indirectly connected.
The terms used throughout this specification generally have their ordinary meanings in the art, within the context of the invention, and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the devices and methods of the invention and how to make and use them. It will be appreciated that the same thing can be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein, nor is any special significance to be placed upon whether or not a term is elaborated or discussed in greater detail herein. Synonyms for certain terms are provided. A recital of one or more synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification, including examples of any terms discussed herein, is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified term.
As used herein, the term “cancer” refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites. The term “cancer” includes, but is not limited to, solid tumors and bloodborne tumors. The term “cancer” encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels. The term “cancer” further encompasses primary and metastatic cancers.
The terms “cells” or “groups of cells” as used herein further encompasses cultured cells that have been explanted from a body or tissue and that have been maintained in vitro in a cell culture system. Examples of such cells include “primary cell” cultures. Primary cells are those cells that are explanted directly from a donor organism or tissue. Primary cells may typically be capable of undergoing a limited number of divisions in culture, but they generally do not continue to grow and eventually senesce and die.
Further examples of isolated cells include “secondary cell” cultures. Secondary cells are those cells that are explanted directly from a donor organism or tissue and that are maintained and propagated in culture for a protracted period of time, typically exceeding that of primary cells. Often times, secondary cells may be propagated in vitro for up to as many as 100 generations or more. Secondary cells are typically not immortalized however, and eventually undergo senescence. The number of cell divisions that secondary cells may undergo is related to their degree of differentiation. More terminally differentiated cells undergo fewer cell divisions and senesce early. Less well-differentiated cells, such as embryonic fibroblasts and cells that have begun to undergo neoplastic transformation, typically have a higher generation potential and can undergo a greater number of divisions.
Yet further examples of isolated cells include “immortalized cells.” Immortalized cells may typically be maintained and propagated in vitro indefinitely as long as the correct culture conditions are maintained. Immortalized cell lines are commonly referred to in the art as “transformed cells.” The growth properties of such cells are altered. Typically, such cells have undergone one or more genotypic changes, such as, for example point mutations, aneuploidy or other chromosomal alterations. Immortalized cells may or may not be cancerous or malignant. Non-malignant transformed cells typically exhibit one or more of several properties when grown in vitro. Non-limiting examples of the phenotypic properties exhibited by non-malignant transformed cells include anchorage-dependent growth, growth factor dependence, and growth-arrest under conditions of nutritional deficiency. Furthermore, while transformed cells are generally not as highly differentiated as their primary or secondary counterparts, they nonetheless typically retain at least a subset of the morphological and biochemical properties of the cell type from which they are derived. Finally, non-malignant cells exhibit a growth property known in the art as “contact inhibition.” Typically, such cells will continue to grow and divide in vitro when plated at low density. When the density of cells is sufficient so that a “monolayer” of cells has formed (i.e., the borders of adjacent cells are substantially touching), growth inhibitory signals pass between the cells, the cells exit the cell cycle and cease dividing. Such “contact inhibited” cells are frequently coupled by gap junctions. Loss of contact inhibition is a widely regarded sign that cells have become cancerous or oncogenic. Such cells do not stop dividing when they form a monolayer in culture. Rather, they continue to divide and pile up on top of one another in “foci”. It is generally well accepted by ordinary practitioners of the art that cells that form foci in culture are tumor cells.
As used herein, the term “neoplastic transformation” or “oncogenic transformation,” generally refers to a proliferative disorder of cells characterized by one or more of several cellular changes. Such cellular changes are manifested by cells that have become, or are on the way to becoming, cancerous or malignant. Characteristics of cells that have undergone neoplastic transformation are well known to ordinary practitioners of the art and may include, but are not limited to, loss of contact inhibition, escape from control mechanisms, loss of GJIC, increased growth potential, increased growth rate, the ability to form colonies in soft agar, alterations in the cell surface, alterations in the expression of certain protein or gene markers, karyotypic abnormalities, aneuploidy, morphological and biochemical deviations from the norm, and other attributes that confer the ability of the cell or group of cells to invade, metastasize, and kill. Neoplastic transformation may be induced, at least in part, by exposure of a cell or group of cells to radiation, or to one or more oncogenic agents such as certain viruses or carcinogens. A “carcinogen” as used herein, generally refers to a substance that increases the likelihood that a cell or group of cells begins the process of neoplastic transformation. Carcinogens may include genotoxic agents, also known in the art as “mutagens”, and non-genotoxic agents, which induce neoplasms by non-genomic mechanisms.
The term “apoptosis,” as used herein, generally refers to a morphologically distinct form of programmed cell death that is important in the normal development and maintenance of multicellular organisms. Dysregulation of apoptosis can take the form of inappropriate suppression of cell death, as occurs in the development of cancers, or in a failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders. Apoptosis is an active process in which cells induce their self-destruction in response to specific cell death signals or in the absence of cell survival signals. It is distinct from necrosis, which is cell death occurring as a result of severe injurious changes in the environment. Apoptosis of a cell can be characterized at least by the rapid condensation of the cell with collapse of the nucleus but preservation of membranes; or, cleavage of nuclear DNA at the linker regions between nucleosomes to produce fragments which can be easily visualized by agarose gel electrophoresis as a characteristic ladder pattern. Cells undergoing apoptosis exhibit a characteristic series of morphological changes including mitochondrial membrane swelling and rupture, leakage of cytosolic contents into the surrounding area, and inflammation in tissues. The pattern of events occurring during apoptosis is orderly and includes; cell shrinkage; appearance of bubble-like blebs on their surface; degradation of chromatin (DNA in a complex with protein and RNA) in their nucleus; mitochondrial rupture and release of cytochrome c into the cytosol; breakage of the cell into small, membrane-wrapped, fragments (commonly referred to as “apoptotic bodies” or “corpses”); exposure of phosphatidylserine on the outer leaflet of the cell membrane; and recruitment of phagocytic cells like macrophages and dendritic cells which then engulf the cell fragments.
Various pathologies occur due to a defective or aberrant regulation of apoptosis in the affected cells of an organism. For example, defects that result in a decreased level of apoptosis in a tissue as compared to the normal level required to maintain the steady-state of the tissue can promote an abnormal increase of the amount of cells in a tissue. This has been observed in various cancers, where the formation of tumors occurs because the cells are not dying at their normal rate.
The terms “reducing,” “inhibiting” and “ameliorating,” as used herein, when used in the context of modulating a pathological or disease state, generally refers to the prevention and/or reduction of at least a portion of the negative consequences of the disease state. When used in the context of an adverse side effect associated with the administration of a drug to a subject, the term(s) generally refer to a net reduction in the severity or seriousness of said adverse side effects.
As used herein, the term “systemically,” when used in the context of a physiological parameter, generally refers to a parameter that affects the entire body of a subject, or to a particular body system.
As used herein the terms “administration,” “administering,” or the like, when used in the context of providing a pharmaceutical or nutraceutical composition to a subject generally refers to providing to the subject one or more pharmaceutical, “over-the-counter” (OTC) or nutraceutical compositions in combination with an appropriate delivery vehicle by any means such that the administered compound achieves one or more of the intended biological effects for which the compound was administered. By way of non-limiting example, a composition may be administered parenteral, subcutaneous, intravenous, intracoronary, rectal, intramuscular, intra-peritoneal, transdermal, or buccal routes of delivery. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, weight, and/or disease state of the recipient, kind of concurrent treatment, if any, frequency of treatment, and/or the nature of the effect desired. The dosage of pharmacologically active compound that is administered will be dependent upon multiple factors, such as the age, health, weight, and/or disease state of the recipient, concurrent treatments, if any, the frequency of treatment, and/or the nature and magnitude of the biological effect that is desired.
As used herein, the term “treat” in the context of animals generally refers to an action taken by a caregiver that involves substantially inhibiting, slowing or reversing the progression of a disease, disorder or condition, substantially ameliorating clinical symptoms of a disease disorder or condition, or substantially preventing the appearance of clinical symptoms of a disease, disorder or condition.
As used herein, terms such as “pharmaceutical composition,” “pharmaceutical formulation,” “pharmaceutical preparation,” or the like, generally refer to formulations that are adapted to deliver a prescribed dosage of one or more pharmacologically active compounds to a cell, a group of cells, an organ or tissue, an animal or a human. Methods of incorporating pharmacologically active compounds into pharmaceutical preparations are widely known in the art. The determination of an appropriate prescribed dosage of a pharmacologically active compound to include in a pharmaceutical composition in order to achieve a desired biological outcome is within the skill level of an ordinary practitioner of the art. A pharmaceutical composition may be provided as sustained-release or timed-release formulations. Such formulations may release a bolus of a compound from the formulation at a desired time, or may ensure a relatively constant amount of the compound present in the dosage is released over a given period of time. Terms such as “sustained release” or “timed release” and the like are widely used in the pharmaceutical arts and are readily understood by a practitioner of ordinary skill in the art. Pharmaceutical preparations may be prepared as solids, semi-solids, gels, hydrogels, liquids, solutions, suspensions, emulsions, aerosols, powders, or combinations thereof. Included in a pharmaceutical preparation may be one or more carriers, preservatives, flavorings, excipients, coatings, stabilizers, binders, nanoparticles, solvents and/or auxiliaries that are, typically, pharmacologically inert. It will be readily appreciated by an ordinary practitioner of the art that, pharmaceutical compositions, formulations and preparations may include pharmaceutically acceptable salts of compounds. It will further be appreciated by an ordinary practitioner of the art that the term also encompasses those pharmaceutical compositions that contain an admixture of two or more pharmacologically active compounds, such compounds being administered, for example, as a combination therapy.
The term “pharmaceutically acceptable salts” includes salts prepared from by reacting pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases, with inorganic or organic acids. Pharmaceutically acceptable salts may include salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, etc. Examples include the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-dibenzylethylenediamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.
As used herein the terms “subject” generally refers to a mammal, and in particular to a human.
Terms such as “in need of treatment,” “in need thereof,” “benefit from such treatment,” and the like, when used in the context of a subject being administered a pharmacologically active composition, generally refers to a judgment made by an appropriate healthcare provider that an individual or animal requires or will benefit from a specified treatment or medical intervention. Such judgments may be made based on a variety of factors that are in the realm of expertise of healthcare providers, but include knowledge that the individual or animal is ill, will be ill, or is at risk of becoming ill, as the result of a condition that may be ameliorated or treated with the specified medical intervention.
By “therapeutically effective amount” is meant an amount of a drug or pharmaceutical composition that will elicit at least one desired biological or physiological response of a cell, a tissue, a system, animal or human that is being sought by a researcher, veterinarian, physician or other caregiver.
The term “pharmacologically inert,” as used herein, generally refers to a compound, additive, binder, vehicle, and the like, that is substantially free of any pharmacologic or “drug-like” activity.
In an embodiment, a method of treating cancer in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising a bisamidoxime. As described herein, bisamidoximes have been shown to be effective against a plurality of types of cancer, including but not limited to breast, lung, and colon cancer.
In an embodiment, a method of treating cancer in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising one, two or more bisamidoximes.
In some embodiment, bisamidoximes have the structure:
where W: is —(CH₂)₂—; —(CH₂)₃—; —(CH₂)₄—; or —(CH₂)₃—N(CH₃)—(CH₂)₃—; and where Y is H, C₁-C₆alkyl, or halogen. In a preferred embodiment, bisamidoximes have the structure above where Y is methyl. Specific examples of bisamidoximes include, but are not limited to JJMB 5, JJMB 6, JJMB 7, and JJMB 9:
In some embodiments, using a combination of two or more bisamidoximes produces a synergistic effect that enhances the effectiveness of the pharmaceutical composition. Synergistic effects have been observed in combinations of: JJMB5 and JJMB 9; JJMB5 and JJMB7; and JJMB7 and JJMB9.
In another embodiment, a method of treating cancer in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising an anticancer agent and one or more bisamidoximes. As described herein, a combination of a known anticancer agent and one or more bisamidoximes have been shown to be effective against a plurality of types of cancer, including but not limited to breast and colon cancer.
As used herein, the term “anticancer agent” refers to any agent that is administered to a subject with cancer for purposes of treating the cancer. Use of the subject bisamidoximes may be particularly advantageous and may enhance the effectiveness of the anticancer agent. Non-limiting examples of anticancer agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and analogs or metabolites thereof, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide); DNA intercalators (e.g., cisplatin, oxaliplatin, and carboplatin); DNA intercalators and free radical generators such as bleomycin; nucleoside mimetics (e.g., 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea); cell replication disrupters (e.g., paclitaxel, docetaxel, and related analogs; vincristine, vinblastin, and related analogs; thalidomide and related analogs (e.g., CC-5013 and CC-4047)); protein tyrosine kinase inhibitors (e.g., imatinib mesylate and gefitinib); antibodies which bind to proteins overexpressed in cancers and thereby downregulate cell replication (e.g., trastuzumab, rituximab, cetuximab, and bevacizumab); and other inhibitors of proteins or enzymes known to be upregulated, over-expressed or activated in cancers, the inhibition of which downregulates cell replication.
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Nine novel bisamidoximes were tested for their potential to inhibit growth of malignant cell-lines in culture conditions. The bisamidoximes were synthesized according to the procedure set forth in the paper to Johnson et al. “Bisamidoximes: Synthesis and Complexation with Iron(III)”, Aust. J. Chem. 2007, 60, 685-690, which is incorporated herein by reference.
Table 1 summarizes the results of the testing of the nine novel bisamidoximes. In Table 1, the various compounds listed were tested for induction of death in various malignant human cell lines and were compared to the commercial HAT inhibitor garcinol (0.2-500 PM). Specifically, Table 1 describes the summary of the growth inhibitory effect (in μM) of nine novel bisamidoximes on six malignant cell lines, as measured by MTS assay. MTS assay is a colorimetric based cytotoxicity assay that determines the number of viable cells. The numbers in the table represent Growth Inhibition GI₅₀(±standard deviation), which is the concentration of the drug where 50% of the cells are killed. Garcinol, a known HAT inhibitor, was used as a positive control. The cell lines used were: HCT-116 (colorectal carcinoma), DU-145 (prostate carcinoma), SK—OV-3 (ovarian adenocarcinoma), HLF-a (lung epidermoid carcinoma), MCF-7 & MDA-MB-231 (breast adenocarcinoma) and NHDF (normal human dermal fibroblasts). The cells were treated with compounds JJMB 1-9 for 48 hrs (MCF-7 for 72 hrs) at various concentrations ranging from 0.2 M to 500 M. One-way ANOVA was performed to assess the differences between the groups. Differences in means between control and treatment groups were analyzed by post-hoc Dunnett's test, p<0.05. Data is reported as the mean±SD, n=3. N-No inhibition; *—represents results from highly purified and more potent batches of the compounds. The compounds tested (JJMB5, JJMB6, JJMB7, and JJMB9) could efficiently kill several malignant cell-lines in concentration range of micromolars. (See Table 1). Furthermore the compounds tested did not kill normal human dermal fibroblast cells (NHDF) at these concentrations, making them good candidates for continuing biochemical, pharmacological, and eventually medical studies. From these test it is clear that the compounds affected several cells lines of the three major types of cancers: breast, lung, and colon.
Since the various potent amidoximes demonstrated a distinct pattern of cytotoxicity by killing different cell lines, it suggested that each of these compounds has a different mechanism of action. To further understand the mechanism of action of the four active compounds (JJMB5, JJMB6, JJMB7, and JJMB9), we performed several experiments that are summarized in Table 2. All the assays were performed on HCT-116 (a colorectal carcinoma), since all of the four specific potent drugs could induce death of these cells. The assays demonstrated that all the compounds induced apoptosis of cells (programed cell death), and all of them reduced the acetylation levels of core histones H3K9 and H4K5 in HCT-116 cells, which suggested that these compounds are HAT inhibitors. JJMB9 indeed inhibited the activity of a purified recombinant HAT-p300 in vitro (in a tube). Another HAT, GCN5, was not inhibited by any of the compounds. JJMB5, JJM6 and JJMB9 could reverse the activity of an HDAC inhibitor (TSA); thus the hyperacetylation induced by TSA could be reversed by these compounds.

TABLE 1

Induction of death in malignant human cell lines by bisamidoximes ( JJMB
5, 6, 7, and 9), and the commercial HAT inhibitor garcinol (0.2-500 μM)

Cell Line	JJMB5	JJMB6	JJMB7	JJMB9	Garcinol

Colon (HCT-116)	8.5* ± 2.5	17 ± 4	6.2* ± 2	16* ± 3.4	39 ± 8
Lung (HLF-A)	335 ± 4	N	275 ± 3	40 ± 7	27 ± 4
Breast (MCF-7), 72 hours	33.2* ± 6.0	N	N	8.5* ± 2.5	55 ± 7
Breast (MDA-MB-231)	125 ± 4	N	85 ± 3	N	44 ± 4
Prostate (DU-145)	N	N	N	N	55 ± 7
Ovarian (SKOV-3)	N	N	N	N	43 ± 5
Normal (NHDF)	N	N	N	N	N

TABLE 2

Comparison of various characteristics of the bisamidoximes
that specifically killed malignant cells in culture

ACTIVITY	JJMB5	JJMB6	JJMB7	JJMB9

Induction of apoptosis	+	+	+	+
in HCT-116 cells
Inhibition of histones H3K9	+	+	+	+
acetylation in HCT-116 cells
Inhibition of histones H4K5	+	+	+	+
acetylation in HCT-116 cells
Inhibition of histones H3K27	+	+	−	+
acetylation in HCT-116 cells
Inhibition of the HAT	−	−	−	+
p300 in vitro
Inhibition of the HAT	−	−	−	−
GCN5 in vitro
Reversion of HDAC-inhibitor-	+	+	−	+
induced hyperacetylation
Inhibition of core histone	+	+	−	+
acetylation in vivo prior
to onset of apoptosis
Induction of G1/S arrest	−	+	+	+
Induction of G2/M arrest	+	−	−	−

This is another indication that the three compounds, JJMB5, JJMB6, and JJMB9 are HAT inhibitors. However, bisamidoxime JJMB7 could not reverse the TSA-induced hyperacetylation, indicating that it is not a HAT inhibitor. In accord with this notion, JJMB7 did not demonstrate inhibition of core histones acetylation in vivo prior to the onset of apoptosis, as opposed to JJMB5, JJMB6 and JJMB9. This result indicated that JJMB7 induces an indirect decrease of acetylation, not by inhibiting HATs, but by some alternative mechanism. The overall picture that emerges from the data presented in Tables 1 and 2 suggests that each of the four bisamidoximes that showed cell-death induction activity has a different mode of action.
Though the compounds induced apoptosis (programmed cell death) of several malignant lines, due to the fact that two different breast cancer cell lines, one estrogen receptor positive and the other estrogen receptor negative, were sensitive to the bisamidoximes, and due to the very high incidence of breast cancer, our approach in the experimental work was to focus on breast cancer. However, it should be understood that the results set forth herein are applicable to other forms of cancer, particularly colon cancer and lung cancer.
The efficacy of killing malignant cells in mice and slowing down the tumors or eradicating them can be indicative to these compounds' efficacy in humans. To check if the bisamidoximes are potent in mice, breast cancer cells were identified that could be implanted in female mice mammary fat pads. The identified cells were tested to see if they are sensitive to bisamidoximes in vitro (in tube/cell culture).
It was found that the murine mammary cancer cell line 4T1 (and also the EpH4 cells) was highly sensitive to three bisamidoximes that killed human breast cell lines (JJMB5, JJMB7, and JJMB9). The growth inhibition 50% (GI₅₀) of the various drugs on 4T1 cells were as follows: JJMB5 -6.3±2.3 μM; JJMB7 -14.7±6.3 μM; and JJMB9 -33.3+2.4 μM. At the next stage, we needed to determine whether the mice would tolerate the drugs, or in other words, what would be the maximum tolerated dose (MTD) of each of the bisamidoximes. The three bisamidoximes JJMB5, JJMB7, and JJMB9, as well as a control group of only the vehicle (the solvent used to dissolve the drugs) were injected intraperitoneally (IP) to mice. The protocol included injection of the desired concentration of bisamidoxime over 5 consecutive days, two days of break, and another cycle of 5 successive days of injections. It was determined that the maximum tolerated doses in mice (BALB/c strain) were as follows: JJMB5-0.26 mg/kg; JJMB7-1.56 mg/kg; and JJMB9-0.78 mg/kg.
The bisamidoxime JJMB7 was studied to see if the compound can lower the rate of tumor growth and the number and size of metastases in mice. JJMB7, was found to significantly reduce the mammary carcinoma tumor volume when injected IP. FIG. 2 depicts a graph of mammary tumor volumes in JJMB7 treated and untreated control BALB/c mice. In the experiment, six-week-old BALB/c mice were implanted with 10,000 4T1 breast carcinoma cells in the mammary fat pad (MFP). The next day, 10 mice were injected IP with the maximum tolerated dose (MTD) of 1.56 mg/kg of JJMB7, and 10 control mice were injected with the vehicle alone. JJMB7 was administered for five consecutive days, followed by a two day break, and another five consecutive days of injections. Mice were weighed every day and observed for signs of pain and discomfort. Tumors were visible 7 days after implantation, and tumor dimensions were measured, and volumes were calculated until day-24, when mice were euthanized. A One-Way Repeated Measures ANOVA was performed to determine a statistical significance (p≤0.05).
In parallel to the in vivo testing, tests were performed to study the efficacy of various combinations of the bisamidoximes on killing human malignant cancer cells in culture. Since each of our four compounds being tested have a different mode of action, each of the compounds most likely have a different molecular target in the cells.
The results of various tests of combinations of bisamidoximes on malignant cancer cell lines are summarized in Table 3. Combination studies performed on human breast cancer cell line MCF-7 and human colon cancer cell line HCT 116 were measured by MTS assay. The cells were treated with novel bisamidoximes JJMB 5, 7, and 9, for 48 hours (72 hours for MCF-7), individually or in combination. Growth Inhibition (GI₅₀) was measured. *—Indicates a significant difference when the drugs were used in combination compared to when the drugs were used individually as determined by one-way ANOVA, p≤0.05.

TABLE 3

Combination studies of novel bisamidoximes
on malignant cell lines

Cell Line	Amidoxime	Growth Inhibition (GI₅₀) in uM

MCF-7	JJMB5	28.2 ± 7.1
	JJMB9	5.3 ± 2.7
	JJMB5 & JJMB9	5.1 ± 3.3*
HCT-116	JJMB5	20.4 ± 3.6
	JJMB9	20.9 ± 3.5
	JJMB5 & JJMB9	9.4 ± 2.2*
	JJMB5	22.4 ± 1.1
	JJMB7	15.5 ± 5.6
	JJMB5 & JJMB7	5.7 ± 1.4*
	JJMB7	25.2 ± 1.7
	JJMB9	22.4 ± 4.4
	JJMB7 & JJMB9	7.2 ± 1.5*
4T1	JJMB5	7.8 ± 3.2
	JJMB9	26.1 ± 5.9
	JJMB5 & JJMB9	3.4 ± 0.8
	JJMB5	8.2 ± 0.1
	JJMB7	7.1 ± 0.8
	JJMB5 & JJMB7	3.2 ± 0.7*
	JJMB7	8.0 ± 0.6
	JJMB9	30.2 ± 2.0
	JJMB7 & JJMB9	4.2 ± 0.6*

The results described in Table 3 demonstrate that combinations of JJMB5 and JJMB9, JJMB5 and JJMB7, or JJMB7 and JJMB9 were more efficient in killing the colon cancer cells HCT-116 (lower GI₅₀s) than using each of the bisamidoximes alone. The same combinations were also more efficient in inducing the death of the murine mammary carcinoma cells 4T1.
The results of various tests of combinations of bisamidoximes with cisplatin on malignant cancer cell lines are summarized in Table 4.

TABLE 4

Combination studies of cisplatin and novel
bisamidoximes on human malignant cell lines

Cell Line	Amidoxime	Growth Inhibition (GI50) in μM

MCF-7	JJMB5	33.2 ± 6.0
	Cisplatin	48.5 ± 6.5
	JJMB5 & Cisplatin	17.2 ± 3.8*
	JJMB9	8.5 ± 2.5
	Cisplatin	40.8 ± 2.6
	JJMB9 & Cisplatin	5 ± 1.2*
HCT-116	JJMB5	19.3 ± 2.4
	Cisplatin	68.6 ± 8.5
	JJMB5 & Cisplatin	7.9 ± 0.5*
	JJMB7	16.2 ± 2.0
	Cisplatin	73 ± 9.0
	JJMB7 & Cisplatin	6.2 ± 1.0*
	JJMB9	16 ± 3.4
	Cisplatin	66.3 ± 8.4
	JJMB9 & Cisplatin	8.1 ± 1.0*

Combination studies of bisamidoximes and cisplatin were performed on human breast cancer cell line MCF-7, human colon cancer cell line HCT-116, and murine mammary malignant cell lines measured by MTS assay. The cells were treated with novel bisamidoximes JJMB 5, 7, and 9, for 48 hours (72 hours for MCF-7), individually or in combination with cisplatin. Growth Inhibition (GI₅₀) was measured. *—Indicates a significant difference when the drugs were used in combination with cisplatin compared to when the drugs were used individually as determined by one-way ANOVA, p≤0.05.
The results summarized in Table 4 show that the combination of the commonly used chemotherapeutic agent cisplatin and JJMB5, and cisplatin and JJMB9, were more efficient in killing the human breast cancer cells MCF-7. The combination of JJMB5, JJMB7, or JJMB9 with cisplatin was also more efficient in killing the colon carcinoma cells HCT-116. In addition, it appears that the bisamidoximes JJMB5, JJM7, and JJMB9 were more efficient individually than the commercially available and widely used cisplatin.
FIG. 3 shows that compound JJMB9 significantly reduced the breast cancer tumor volume up to day 21 since the implantation of the malignant cells (mouse mammary carcinoma). The murine mammary carcinoma 4T1 cells were implanted in the mammary fat pad of BALB/c female mice (10,000 cells per mice) and a day later we started a protocol of two 5-day cycles (with 2 days break) of chemotherapy delivered IP. The amidoximes were delivered at their MTD level JJMB5 with 0.26 mg/kg, and JJMB9 with 0.78 mg/kg. One-Way Repeated-Measure ANNOVA was performed to show the significance (p≤0.05, n=10).
FIG. 4 shows the daily weight of mice during this experiment, indicating that though the drug-injected mice lost some weight during the first days of injection, they later bounced back to the normal weight range shown by the untreated control mice group. The untreated mice were also transplanted with 4T1 cells, but they were not injected the vehicle or one of the drugs.
FIG. 5 demonstrates our study with Mouse Liver Microsomes which revealed the t1/2 of JJMB9 to be 13 minutes.
The amidoximes described herein contain an amidoxime group, characteristic of some HDAC inhibitors. However, these compounds also have a six-carbon ring connected by a linker, characteristic of some HAT inhibitors. To test if the amidoximes induced reduction of acetylation or increased acetylation levels of core histones, we performed Western blot analysis against acetylated H3K9 and acetylated H4K5 on the whole cell lysates after treating HCT-116 cells with amidoximes for 24 hours at various concentrations. The experiment was repeated three times. Histone H3 lysine 9 (H3K9) and histone H4 lysine 5 (H4K5) are well studied and important sites involved mainly in transcriptional regulation.
FIG. 6 depicts the effect of JJMB 5, 6, 7, 9 and garcinol on cellular core histone acetylation. The acetylation levels of core histones in HCT-116 cells were measured following treatment for 24 hours at concentrations ranging from 0.04 μM to 80 μM. HCT-116 cells (Panels a-e) were incubated with the amidoximes for 24 hours and then lysed. Western blot analysis was conducted by using antibodies against Ac-H3K9 and Ac-H4K5. Coomassie staining of the SDS-PAGE was done to demonstrate equal loading of the protein. a) Significant reduction in acetylation levels is seen at a concentration of 20 μM and higher after JJMB 5 treatment. b) JJMB 6 treatment resulted in reduction of acetylation levels at 30 μM on H3K9 and H4K5. c) JJMB 7 treatment resulted in reduced acetylation levels at 40 μM and higher concentrations. d) JJMB 9 treatment resulted in complete inhibition of acetylation levels seen at 40 μM. e) Garcinol, used as a positive control, also showed reduced core histone acetylation seen at 25 μM and 50 μM. f) No change in acetylation levels was observed in DU-145 cells treated with JJMB 9. DMSO was used as a vehicle control and applied at concentrations used at the highest amidoxime treatment, in percentage ranging from 0.04%-0.08%. These results suggest that, amidoximes that induced death of HCT-116 cells reduced the core histone acetylation in vivo.
To determine if induction of death in cancer cells is correlated with reduced core histone acetylation, this experiment was repeated with DU-145 cells prostate carcinoma. By MTS cell viability assay, we demonstrated that DU-145 cells were not killed by JJMB 9 (see Table 1). Therefore, we treated DU-145 cells for 24 hours with increasing doses of JJMB 9 and Western blot analysis was performed to test the acetylation levels of core histones with antibodies against Ac-H3K9 and Ac-H4K5. The results showed that JJMB 9 did not inhibit the levels of acetylation on Ac-H3K9 and Ac-H4K5 in DU-145 cells (FIG. 6 , f). These results suggest that the inhibition of core histone acetylation occurred only in the cells that were killed by amidoximes.
FIG. 7 depicts the percentage of standardized acetylation on H3K9 (FIG. 7A) and H4K5 (FIG. 7B) which was calculated by normalizing the acetylation levels to the O.D of the core histones obtained by densitometry of coomassie staining. This graph represents the means of 3 individual experiments. One-way ANOVA was performed to determine the differences between the groups. Pair-wise comparison was done to find out the significance between control group and treatment groups. These results were confirmed by Kruskal Wallis and Mann-U-Whitney non-parametric tests. Levels of significance were designated as *p≤0.05. Data is reported as the mean±SEM (n=3).
The reduced core histone acetylation in cells treated with amidoximes can be explained mainly in three ways:

- 1) The amidoximes inhibit histone acetyltransferases (HATs) directly or indirectly.
- 2) The amidoximes activate histone deacetylases (HDACs) directly or indirectly.
- 3) The amidoximes increase the expression levels of HDAC genes or decreases the expression levels of HAT genes in the cell.

TSA (trichostatin A) is an HDAC inhibitor that inhibits class I and II HDACs but not class III HDACs. The inhibition of HDACs causes the hyperacetylation of lysine residues on the core histone tails. In the previous experiment, we demonstrated that amidoximes caused reduction in core histone acetylation in HCT-116 cells (see FIGS. 6 and 7). The primary reason for the reduced acetylation levels caused by amidoximes could be due to the inhibition of HATs. Our hypothesis is that, cells treated with a combination of HDAC inhibitor, TSA and amidoximes would reverse the TSA induced hyperacetylation. FIG. 8 depicts a schematic diagram of the inhibition of HDACs by TSA and how this induces hyperacetylation of core histones. Inhibition of HATs on the other hand causes hypoacetylation.
To determine if amidoximes can reverse the TSA induced-hyperacetylation, we treated cells with each amidoxime alone, TSA alone and each amidoxime together with TSA for 24 hours and cell lysates were extracted. Western blot analysis was performed using antibodies against acetylated H3K9 and acetylated H4K5. DMSO treated cells (Lane 1, FIG. 9 a-e ) showed basal acetylation of core histones, followed by a dramatic increase in acetylation levels upon TSA treatment (Lane 2, FIG. 9 a-e). The positive controls, amidoxime alone (Lane 6, FIG. 9 a-d) and garcinol alone (Lane 5, FIG. 9 e ) showed inhibition of acetylation levels compared to DMSO treated cells (Lane 1, FIG. 9 a-e). The co-treatment of HCT-116 cells with the positive control, garcinol at 25 μM and TSA resulted in the reduced acetylation levels of core histones when compared to TSA alone treated cells (Lane 2, FIG./9e). The co-treatment of HCT-116 cells with amidoximes JJMB 5 (20 μM and 40 μM) or JJMB 6 (30 μM and 45 μM) or JJMB 9 (20 μM and 40 μM) and TSA showed reduced acetylation levels compared to TSA alone treated cells (Lane 2, FIG. 9 a-e ). These results suggest that JJMB 5, 6, 9 and garcinol effectively reversed the TSA induced hyperacetylation at higher concentrations, whereas JJMB 7 did not reverse the TSA induced hyperacetylation (FIG. 9 ). Results also support the possibility that amidoximes JJMB 5, 6 & 9 are HAT inhibitors but the possibility of histone hypoacetylation could be an indirect effect as well.
The effect of concomitant treatment with TSA and amidoximes on cell survival was studied. From the previous experiment, we learned that treatment of HCT-116 cells with the combination of TSA and amidoximes reversed the TSA induced hyperacetylation in most cases. Amidoximes reverse the HDAC inhibitor, TSA induced hyperacetylation. HCT-116 cells were treated with amidoximes alone (at the indicated concentrations), TSA alone (0.3 μM) and amidoximes concomitantly with TSA for 24 hours and cell lysates were extracted. Western blot analysis was performed using the antibodies against Ac-H3K9 and Ac-H4K5. JJMB 5, 6 and 9 effectively reversed TSA induced hyperacetylation whereas JJMB 7 did not affect the TSA induced hyperacetylation. Garcinol also opposed the TSA induced hyperacetylation at 25 μM.
Acetylation of core histones is generally involved in activation of gene expression whereas deacetylation of core histones is generally involved in gene repression. Our hypothesis was that reversing the TSA effect by amidoximes would also block the cell death induced by TSA or by the amidoximes. In other words, reversing the TSA effect by amidoximes would bring the global acetylation and gene expression levels to normal steady state levels and therefore the cells would survive. To determine if the amidoximes can block the TSA induced cell death, HCT-116 cells were treated with amidoximes alone (at the indicated concentrations in FIGS. 10A-E), TSA alone (0.3 μM) or TSA incubated along with JJMB 5, 6, 7 and 9 at various concentrations and MTS cell viability assay was performed after 24 hours. One-way ANOVA was performed to assess the differences between groups. Differences in means between TSA treated and TSA along with amidoximes groups were analyzed by post-hoc Dunnett's test,*p≤0.05. Values are mean±SD, n=3. MTS assay was performed to determine cell viability. The results revealed that TSA alone and amidoximes alone effectively induced cell death in HCT-116 cells when compared to DMSO treated cells (FIG. 10 ). When we compared the cells treated with TSA alone and TSA incubated along with amidoximes JJMB 5, 6, 7, 9 and garcinol, no significant blocking of cell death was observed in any of the compounds tested except for JJMB 5 at 8 μM with TSA. These results indicate that the reason for the cell death is not simply a change in the global acetylation steady state of core histones but something more complex.
JJMB 9 is a p300 inhibitor
The previous experiments have shown the inhibition of core histone acetylation in HCT-116 cells when treated with amidoximes (see FIG. 6 ). This was also supported by the fact that JJMB 5, 6, and 9 reversed the TSA induced hyperacetylation suggesting that inhibition of core histone acetylation levels could be due to the inhibition of histone acetyltransferases (HATs) (see FIG. 9 ). This prompted us to examine if these amidoximes can inhibit the HATs in vitro. To test this hypothesis, we selected p300, a HAT from p300/CBP family which is capable of acetylating free and nucleosomal histones both in vitro and in vivo. The HAT inhibitory activity was assayed using full length human recombinant p300, purified core histones from chicken erythrocytes and acetyl coA as the substrates. FIG. 11 depicts a diagram showing the experimental design of the in vitro HAT assay in the presence and absence of inhibitor. Western blot analysis was performed to determine if the amidoximes inhibited the p300-dependent acetylation on H3K9 and H4K5. FIG. 12 depicts results of the in vitro P300 inhibition assay. In vitro histone acetyltransferase inhibition (HAT) assay was performed using acetyl CoA (72 μM) and purified core histones as substrates for the HAT p300 (Calbiochem) in the absence or presence of increased concentrations of JJMB 5, 6, 7 and 9 (8 μM-1000 μM). DMSO was used as a vehicle control (lane 2). Garcinol, a known HAT p300 inhibitor was used as a positive control. Reaction mixtures were run on 15% SDS-PAGE and Western blot was performed using antibodies against Ac-H4K5 and Ac-H3K9. Lane 1 represents the basal acetylation levels of H3K9 and H4K5. Increase in the acetylation levels was observed in lane 2 upon p300 addition (FIG. 12 ).
FIG. 13 depicts the percentage of standardized acetylation of H4K5. p300 dependent acetylation activity of histone H4K5 was inhibited by JJMB 9 in a dose dependent manner as compared to the DMSO control. One-way ANOVA was performed to determine the significance of the differences between the groups. Post-hoc Dunnett's test was done to find out the significance between control group and treatment groups. Levels of significance based on post-hoc Dunnett's test were designated as *p≤0.05 & **p≤0.01. Data is reported as the mean±SEM of three experiments.
As expected garcinol inhibited the p300-dependent acetylation on H3K9 at 20 μM and at 5 μM on H4K5 compared to DMSO. JJMB 5, 6 and 7 didn't inhibit p300-dependent acetylation in vitro. In contrast, JJMB 9 was found to inhibit p300 activity in a dose dependent manner with an IC₅₀of 40 μM (FIGS. 12 and 13 ). The p300 mediated acetylation was almost completely inhibited at 1000 μM by JJMB 9 compared to DMSO (*p≤0.05) (FIG. 13 ). Garcinol completely inhibited the p300-dependent acetylation at 100 μM whereas JJMB 9 inhibited at 1000 μM with a ten-fold difference. This suggests that garcinol is potent inhibitor of p300 compared to JJMB 9 (FIG. 12 ).
Amidoximes did not inhibit the GCN5 in vitro
Since amidoximes JJMB 5, 6 and 7 did not inhibit the p300 HAT in vitro, we tested the possibility that these amidoximes inhibit another type of HAT. To test this hypothesis, we selected GCN5, GNAT family HAT, which is capable of acetylating histones both in vitro and in vivo. The HAT inhibitory activity was assayed using full length mouse recombinant GCN5 (purified in our lab) and purified core histones and acetyl coA as the substrates. Western blot analysis was performed to determine if the amidoximes inhibit the GCN5-dependent acetylation of Ac-H3K14. For GCN5 inhibition assay, we used only anti Ac-H3K14 antibody since rGCN5 predominantly acetylates histone H3 at lysine 14.
FIG. 14 depicts the results of the in vitro GCN5 inhibition assay. This assay was performed using acetyl CoA (72 μM) and purified core histones (2 μg) as substrates for the HAT GCN5 (purified) in the absence or presence of increased concentrations of JJMB 5, 6, 7 and 9 (8 μM-500 μM). Anacardic acid, a known HAT GCN5 inhibitor was used as a positive control. Reaction mixtures were run on 15% SDS-PAGE and western blot was performed using antibodies against Ac-H3K14. JJMB 5, 6, 7 and 9 did not inhibit the acetylation activity of GCN5 whereas anacardic acid inhibited the GCN5 acetylation activity in a dose dependent manner. Lane 1 represents the basal acetylation levels of H3K9 and H4K5. Increase in the acetylation levels was observed in lane 2 upon GCN5 addition. As expected anacardic acid inhibited the GCN5-dependent acetylation at 40 μM. The results revealed that JJMB 5, 6, 7 and 9 did not inhibit GCN5-dependent acetylation in vitro.
In this patent, certain U.S. patents, U.S. patent applications, and other materials (e.g., articles) have been incorporated by reference. The text of such U.S. patents, U.S. patent applications, and other materials is, however, only incorporated by reference to the extent that no conflict exists between such text and the other statements and drawings set forth herein. In the event of such conflict, then any such conflicting text in such incorporated by reference U.S. patents, U.S. patent applications, and other materials is specifically not incorporated by reference in this patent.
Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention as described in the following claims.

Claims

1-7. (canceled)

8. A pharmaceutical composition comprising one or more bisamidoximes, wherein the one or more bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB6, and JJMB 9:

9. The pharmaceutical composition of claim 8, comprising two or more bisamidoximes.

10. The pharmaceutical composition of claim 8, comprising JJMB5 and JJMB 9.

11. The pharmaceutical composition of claim 8, comprising JJMB5.

12. The pharmaceutical composition of claim 8, comprising JJMB6.

13. The pharmaceutical composition of claim 8, comprising JJMB 9.

14. The pharmaceutical composition of claim 8, further comprising an anticancer agent.

15. The pharmaceutical composition of claim 14, wherein the anticancer agent is cisplatin.

16. The pharmaceutical composition of claim 8 being a therapeutically effective amount for inhibiting histone acetyltransferases (HATs) in a HAT malfunction related pathology.

17. The pharmaceutical composition of claim 8 being a therapeutically effective amount for treating colon cancer, breast cancer, or lung cancer in a subject.

18. A pharmaceutical composition comprising one or more bisamidoximes, wherein the one or more bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB6, JJMB 7, and JJMB 9:

19. The pharmaceutical composition of claim 18, comprising two or more bisamidoximes.

20. The pharmaceutical composition of claim 18, comprising JJMB5 and JJMB 9.

21. The pharmaceutical composition of claim 18, comprising JJMB5 and JJMB7.

22. The pharmaceutical composition of claim 18, comprising JJMB7 and JJMB 9.

23. The pharmaceutical composition of claim 18, comprising JJMB 7.

24. The pharmaceutical composition of claim 18, further comprising an anticancer agent.

25. The pharmaceutical composition of claim 24, wherein the anticancer agent is cisplatin.

26. The pharmaceutical composition of claim 18 being a therapeutically effective amount for inhibiting histone acetyltransferases (HATs) in a HAT malfunction related pathology.

27. The pharmaceutical composition of claim 18 being a therapeutically effective amount for treating colon cancer, breast cancer, or lung cancer in a subject.